Status:
NOT_YET_RECRUITING
French National Cohort of Patients With Rifampicin-Resistant Tuberculosis
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Rifampicin-resistant Tuberculosis
Eligibility:
All Genders
Brief Summary
A major obstacle in the fight against multidrug-resistant tuberculosis is its treatment. In 2021, only 60% of patients with MDR/RR tuberculosis who received treatment globally were successfully cured,...
Detailed Description
Tuberculosis (TB) is a major global health problem. Over the past decade, Mycobacterium tuberculosis has killed more people worldwide than any other infectious pathogen, and drug-resistant TB accounts...
Eligibility Criteria
Inclusion
- Patient treated for MDR/RR tuberculosis
- In the major reference centres in the Paris region (CHU Pitié-Salpêtrière and Bichat \[Paris\], CH Bligny \[Briis-sous-Forges\]) for the retrospective part;
- Throughout France (national register) for the prospective part.
Exclusion
- None
Key Trial Info
Start Date :
September 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2032
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06565806
Start Date
September 1 2024
End Date
September 1 2032
Last Update
August 22 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.